每4周7400 MBq 177Lu-PSMA-617标准化治疗的疗效与生存预测
该回顾性研究纳入61例转移性去势抵抗性前列腺癌患者,均每4周接受7400 MBq 177Lu-PSMA-617治疗三个周期。基线血红蛋白可预测PSA下降≥50%及生存,基线PSA≤650 μg/L和正常血红蛋白水平与更长生存相关。
要点
- 基线血红蛋白独立预测PSMA-RLT的PSA应答和生存。
- 基线PSA≤650 μg/L者生存显著长于>650 μg/L者。
- 既往阿比特龙/恩扎卢胺或多西他赛/卡巴他赛治疗不影响应答与生存。
核心结论
- 基线血红蛋白水平是每4周7400 MBq 177Lu-PSMA-617治疗患者疗效和生存的独立预测因素。
- 基线PSA≤650 μg/L和正常血红蛋白水平均与更长生存相关。
研究设计与样本
- 回顾性分析61例转移性去势抵抗性前列腺癌患者,平均年龄71.6±6.9岁,中位基线PSA 70.7 μg/L(范围1.0-4890)。
- 所有患者每4周接受三个周期PSMA-RLT,平均给药活度7321±592 MBq。
- 75.4%患者既往接受阿比特龙/恩扎卢胺治疗,68.9%接受多西他赛/卡巴他赛治疗。
- 疗效基于第三周期后1个月PSA水平评估,采用二元逻辑回归和Kaplan-Meier法分析预测因素和总生存。
主要发现
- 基线血红蛋白显著预测第三周期后4周PSA下降≥50%(P=0.01,95%CI:1.09-2.09),AUC为0.68(95%CI:0.54-0.81)。
- 基线血红蛋白和基线PSA均可预测生存,P均<0.05,相对风险分别为1.51(95%CI:1.09-2.09)和0.79(95%CI:0.43-1.46)。
- 基线血红蛋白正常者生存显著长于降低者(中位生存未达到 vs. 89周,P=0.016)。
- 基线PSA≤650 μg/L者生存显著长于>650 μg/L者(中位生存未达到 vs. 97周,P=0.031)。
关键数值与推荐
- 基线血红蛋白预测PSA下降≥50%的P=0.01,95%CI:1.09-2.09,AUC 0.68(95%CI:0.54-0.81)。
- 基线血红蛋白预测生存的相对风险1.51(95%CI:1.09-2.09),P<0.05。
- 基线PSA预测生存的相对风险0.79(95%CI:0.43-1.46),P<0.05。
- 基线血红蛋白正常者中位生存未达到,降低者为89周(P=0.016)。
- 基线PSA≤650 μg/L者中位生存未达到,>650 μg/L者为97周(P=0.031)。
临床怎么用
- 在每4周7400 MBq 177Lu-PSMA-617治疗前,可检测基线血红蛋白和PSA以辅助预测疗效和生存。
- 基线血红蛋白正常且PSA≤650 μg/L的患者可能从PSMA-RLT中获得更长生存。
- 既往阿比特龙/恩扎卢胺或多西他赛/卡巴他赛治疗史及转移分布不影响应答和生存,不应作为排除依据。
局限性
- 回顾性研究,样本量61例。
- 单中心、同质性治疗方案,外推需谨慎。
- 未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). However, identification of reliable prognostic factors is hampered by heterogeneous treatment regimens applied in previous studies. Hence, we sought clinical factors able to predict response and survival to PSMA-RLT in a homogenous group of patients, all receiving 7400 MBq every 4 weeks. PATIENTS AND METHODS: Data of 61 patients (mean age 71.6 ± 6.9 years, median basal PSA 70.7 [range 1.0-4890 μg/L]), pretreated with abiraterone/enzalutamide (75.4%) and docetaxel/cabazitaxel (68.9%), received three cycles of PSMA-RLT (mean 7321 ± 592 MBq) at four weekly intervals and were analyzed retrospectively. General medical conditions and laboratory parameters of every patients were regularly assessed. Response to therapy was based on PSA levels 1 month after the 3rd cycle. Binary logistic regression test and Kaplan-Meier estimates were used to evaluate predictors and overall survival (OS). RESULTS: Forty-nine (80.3%) patients demonstrated a therapy response in terms of any PSA decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels. Baseline hemoglobin (Hb) significantly predicted PSA reductions of ≥ 50% 4 weeks after receiving the 3rd PSMA-RLT (P = 0.01, 95% CI: 1.09-2.09) with an AUC of 0.68 (95% CI: 0.54-0.81). The levels of basal Hb and basal PSA were able to predict survival of patients, both P < 0.05 (relative risk 1.51 and 0.79, 95% CI: 1.09-2.09 and 0.43-1.46), respectively. In comparison to patients with reduced basal Hb, patients with normal basal Hb levels lived significantly longer (median survival not reached vs. 89 weeks, P = 0.016). Also, patients with basal PSA levels ≤ 650 μg/L had a significantly longer survival than patients with basal PSA levels > 650 μg/L (median survival not reached vs. 97 weeks, P = 0.031). Neither pretreatments with abiraterone/enzalutamide or docetaxel/cabazitaxel nor distribution of metastasis affected survival and rate of response to PSMA-RLT. CONCLUSION: Basal Hb level is an independent predictor for therapy response and survival in patients receiving PSMA-RLT every 4 weeks. Both baseline PSA ≤ 650 μg/L and normal Hb levels were associated with longer survival.
引用
- Rasul S, Hartenbach M, Wollenweber T, et al. Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 33128131. doi:10.1007/s00259-020-05082-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。